Bausch Health Announces 2026 Gastrointestinal Health Scholars Program

Bausch Health (NYSE: BHC) and its gastroenterology business Salix opened applications for the 2026 Salix Gastrointestinal Health Scholars Program.

Rhea-AI Summary

Bausch Health (NYSE: BHC) and its gastroenterology business Salix opened applications for the 2026 Salix Gastrointestinal Health Scholars Program. The program will award 10 scholarships of up to $10,000 to students living with GI disease for the 2026–2027 academic year. Applications close May 6, 2026, and recipients will be notified in summer 2026. Awards include undergraduate, graduate, and working/single-parent categories. Applicants must submit an online application, references, and an essay about their GI condition and a health care provider's role. More details and eligibility are available at the Salix scholarship webpage.

Argus Feb 11 session

-1.30% close to close Open Argus

Details

News Market Reaction – BHC

On Feb 11, the day this news came out, BHC closed 1.30% below the previous close.

Data tracked by StockTitan Argus for the Feb 11 session.

Market Context

This announcement highlights Bausch Health’s 2026 Salix Gastrointestinal Health Scholars Program, su...

Analysis

This announcement highlights Bausch Health’s 2026 Salix Gastrointestinal Health Scholars Program, supporting 10 students with GI disease with awards up to $10,000 for the 2026-2027 academic year. It reinforces Salix’s positioning in gastroenterology but has limited direct financial impact. In recent months, more material drivers have included a Phase 3 trial miss and ongoing debt exchange and refinancing activity, which remain key context points for assessing the overall risk-reward profile.

Key Figures

Student scholarships: 10 students Scholarship amount: up to $10,000 Program duration: seventh consecutive year +2 more

Student scholarships

10 students

Number of students to receive GI Health scholarships

Scholarship amount

up to $10,000

Maximum scholarship per student in 2026 Salix program

Program duration

seventh consecutive year

Scholarship program continuity as stated by company

Application deadline

May 6, 2026

Closing date for 2026 Salix GI Health Scholars applications

Academic year

2026-2027

Academic year covered by awarded scholarships

Historical Context

5 past events · Latest: Jan 23

5 events

1. Jan 23

   Phase 3 trial update

   24h Move

   -10.1%

   Phase 3 RED-C program missed primary endpoint in hepatic encephalopathy.

2. Jan 21

   Earnings date set

   24h Move

   -2.1%

   Announced date and call details for Q4 and full-year 2025 results.

3. Jan 05

   Conference participation

   24h Move

   +2.6%

   Management presenting strategic update at J.P. Morgan Healthcare Conference.

4. Dec 23

   Debt exchange results

   24h Move

   -1.9%

   Final results of exchanges into 10.00% Senior Secured Notes due 2032.

5. Dec 08

   Early exchange update

   24h Move

   -0.3%

   Reported early tender results for 2028 notes into new 2032 notes.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

gastroenterology, gi, liver diseases

3 terms

gastroenterology medical

"its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced"

Gastroenterology is the medical specialty that diagnoses and treats disorders of the digestive system—think of it as the maintenance and repair work for the body’s plumbing, including the esophagus, stomach, intestines, liver, pancreas and gallbladder. It matters to investors because demand for related drugs, devices and diagnostics is driven by how common and costly these conditions are, how new treatments perform in trials, and how insurers reimburse care, all of which affect company revenues and valuations.

gi medical

"10 exceptional students living with GI disease a scholarship of up to"

GI stands for gastrointestinal, meaning the stomach and intestines and the processes that move and digest food. Investors care because GI symptoms or risks—such as nausea, diarrhea, bleeding or chronic irritation—can affect a drug’s safety profile, prescribing guidelines, product labeling and patient willingness to use a treatment; think of it as the product’s impact on a company’s core delivery pipeline, where problems can slow adoption or trigger extra regulatory scrutiny.

liver diseases medical

"persevere through their GI disorders and liver diseases while still maintaining"

Conditions that harm the liver’s ability to act as the body’s chemical factory and filter, including inflammation, scarring, and loss of function from causes like viruses, alcohol, fat buildup, or immune problems. For investors, liver diseases matter because they drive demand for diagnostics, treatments, hospital care and long-term monitoring—so new drugs, test results, regulatory approvals, or changes in treatment guidelines can affect companies’ revenues, trial outcomes and healthcare spending.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Bausch Health to Provide Scholarships to 10 Students Living with GI Diseases

LAVAL, QC, Feb. 11, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the opening of the 2026 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 exceptional students living with GI disease a scholarship of up to $10,000 as they work to pursue their higher education goals.

"Bausch Health is honored to offer The Salix Gastrointestinal Health Scholarship for the seventh consecutive year. This scholarship financially supports students who are driven to persevere through their GI disorders and liver diseases while still maintaining academic excellence. Salix's commitment to support these patients and make a difference in the lives of all communities we serve remains a top priority," said Aimee Lenar, Executive Vice President, U.S. Pharma, Bausch Health.

Students can apply for this scholarship by completing the online application, submitting letters of reference, and writing an essay on the impact having a diagnosed GI condition has had on their life and the role that a health care provider played in helping to manage their condition. Scholarships are offered to school applicants or current attendees of a two- or four-year college, university, or an advanced (post-high school) vocational or technical school for the 2026-2027 academic year and are available in the following categories:

• Undergraduate Scholar Awards for students pursuing undergraduate degrees.
• Graduate Scholar Awards for students pursuing graduate degrees.
• Working and/or Single Parents Scholar Award for students who are working parents and/or single parents pursuing undergraduate, vocational/technical or graduate degrees.

The application period for the Salix Gastrointestinal Health Scholars Program will close on May 6, 2026, and scholarship recipients will be notified in the summer of 2026. To learn more about the scholarship, including eligibility criteria, terms and conditions, please visit www.salix.com/scholarship.

About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn.  For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.

©2026 Salix Pharmaceuticals or its affiliates.

BHC-ORGANIZATION
Investor Contact:	Media Contacts:
Garen Sarafian	Katie Savastano
ir@bauschhealth.com	corporate.communications@bauschhealth.com
877-281-6642 (toll-free)	(908) 569-3692

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch-health-announces-2026-gastrointestinal-health-scholars-program-302682672.html

SOURCE Bausch Health Companies Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is eligible for the 2026 Salix Gastrointestinal Health Scholars Program (BHC)?

Eligible students are those living with GI disease pursuing post-high-school education. According to the company, applicants must be enrolled in or applying to two- or four-year colleges, graduate programs, or vocational/technical schools for the 2026–2027 academic year and meet category criteria.

How much is each scholarship in the Salix Gastrointestinal Health Scholars Program (BHC)?

Each award is up to $10,000 per recipient. According to the company, the program will grant 10 scholarships of up to $10,000 to support students living with GI disease during the 2026–2027 academic year.

What is the application deadline for the Salix Scholars Program (BHC) in 2026?

The application period closes on May 6, 2026. According to the company, applicants must submit an online application, letters of reference, and an essay before that date; recipients will be notified in summer 2026.

What materials are required to apply for the Salix Gastrointestinal Health Scholarship (BHC)?

Applicants must submit an online application, letters of reference, and a personal essay. According to the company, the essay should describe the impact of a diagnosed GI condition and the role a health care provider played in managing it.

When will 2026 Salix Gastrointestinal Health Scholars be notified and how many winners will there be (BHC)?

Ten scholarship recipients will be notified in summer 2026. According to the company, the program will select 10 students for awards and communicate results to applicants during the summer notification period.